Royal Bank of Canada Buys 49,641 Shares of Dyne Therapeutics, Inc. $DYN

Royal Bank of Canada increased its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 267.6% during the 1st quarter, HoldingsChannel reports. The firm owned 68,188 shares of the company’s stock after buying an additional 49,641 shares during the period. Royal Bank of Canada’s holdings in Dyne Therapeutics were worth $1,236,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in DYN. Creative Planning raised its stake in Dyne Therapeutics by 6.8% during the 3rd quarter. Creative Planning now owns 15,527 shares of the company’s stock valued at $196,000 after buying an additional 986 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Dyne Therapeutics by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after buying an additional 1,440 shares during the last quarter. Hilton Head Capital Partners LLC bought a new stake in shares of Dyne Therapeutics in the first quarter worth $26,000. Caxton Associates LLP grew its holdings in shares of Dyne Therapeutics by 10.9% in the second quarter. Caxton Associates LLP now owns 16,599 shares of the company’s stock worth $158,000 after acquiring an additional 1,627 shares during the period. Finally, Steward Partners Investment Advisory LLC increased its position in Dyne Therapeutics by 102.1% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after acquiring an additional 2,465 shares during the last quarter. Institutional investors own 96.68% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on DYN shares. Morgan Stanley lowered their target price on Dyne Therapeutics from $47.00 to $45.00 and set an “overweight” rating on the stock in a report on Friday, July 31st. TD Cowen began coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They set a “buy” rating for the company. Royal Bank Of Canada upped their price target on shares of Dyne Therapeutics from $30.00 to $35.00 and gave the company an “outperform” rating in a research report on Thursday, July 30th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Dyne Therapeutics in a research note on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Friday, July 17th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $34.42.

Dyne Therapeutics Price Performance

NASDAQ DYN opened at $25.98 on Friday. The business’s fifty day moving average is $23.52 and its 200 day moving average is $19.73. Dyne Therapeutics, Inc. has a fifty-two week low of $11.65 and a fifty-two week high of $27.31. The company has a debt-to-equity ratio of 0.28, a quick ratio of 12.02 and a current ratio of 12.02. The company has a market capitalization of $4.85 billion, a PE ratio of -7.80 and a beta of 1.07.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.33). Sell-side analysts predict that Dyne Therapeutics, Inc. will post -3.47 earnings per share for the current year.

Insider Buying and Selling

In other Dyne Therapeutics news, CFO Erick Lucera sold 2,362 shares of the company’s stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the transaction, the chief financial officer directly owned 121,563 shares in the company, valued at $2,476,238.31. This represents a 1.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Jason P. Rhodes sold 2,160,516 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $25.00, for a total transaction of $54,012,900.00. Following the completion of the sale, the director directly owned 428,946 shares of the company’s stock, valued at approximately $10,723,650. This trade represents a 83.43% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have acquired 6,500 shares of company stock worth $114,000 and have sold 4,139,196 shares worth $99,449,852. 9.46% of the stock is currently owned by company insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.